Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Erlotinib and Temsirolimus for Solid Tumors
|5||Active, not recruiting||
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
† Study has passed its completion date and status has not been verified in more than two years.